Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.4.

EBIT: As of FY2026 Q2, the actual value is USD -17.5 M.

The provided reference, a Form 8-K filing by Contineum Therapeutics, Inc., announces the issuance of a press release regarding the company’s financial results for the second quarter ended June 30, 2026. However, the document explicitly states that actual financial results, operational metrics, cash flow details, or any forward-looking outlook/guidance are not contained within this Form 8-K document. Therefore, no specific financial or operational metrics can be extracted from the given text.